New York Gives Final Approval for Rosetta Genomics' miRview Lung Assay | GenomeWeb

NEW YORK (GenomeWeb News) – Rosetta Genomics said today that the New York State Department of Health has given the company's miRview lung assay final approval for marketing in the state.

As a result, the company can offer the microRNA-based test for the differentiation of the four main subtypes of lung cancer in all 50 states. New York had given the test, launched in July 2011, conditional approval in June.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

In Science this week: a global genetic interaction map for Saccharomyces cerevisiae, and progress made in genomics, precision medicine, and therapeutics.

The price of plane tickets can affect how scientists in different countries choose to collaborate with each other, NPR reports.

The Annals of Improbable Research has awarded the 2016 Ig Nobel Prizes.

Scientific American alleges that the FDA has been "arm-twisting journalists into relinquishing their reportorial independence."